CRP and myocardial infarction: A recent study has indicated that employing interleukin-1β inhibition in individuals with a prior myocardial infarction and a high-sensitivity C-reactive protein level ≥ 2 mg/L may lead to a reduction in cardiovascular adverse events without lowering blood pressure [45].